Three telehealth operators (Juniper, Pilot, Mosh) plus LillyDirect's direct path. TGA September 2025 advertising enforcement reset the marketing landscape. Brand-pharmacy supply only · Australia doesn't have a US-style compounded GLP-1 market. Per-month pricing, what each operator actually offers, who fits where.
I keep getting the same question from different friends in different cities. Here's the version short enough to get through over coffee. The decision today (May 2026) is different from the one a year ago, and the difference is mostly about what you actually want from your supply chain.
A coach in Singapore told me the same thing my doctor friend in Bangkok told me: the people who quit tirzepatide almost all quit between week 6 and week 10. The reason isn't the side effects you'd guess. It's the gap between when the discomfort peaks and when the visible results start showing up.
An afternoon in Sukhumvit, four clinics, the same five questions about Mounjaro at each one. The price quotes ranged from 6,000 to 14,500 baht for the same dose. The medical conversation ranged from 'sign here' to a 30-minute consult. Here's what I learned about how to actually choose.
A friend asked me last week whether to keep paying $179 a month for compounded tirzepatide from her telehealth provider. The honest answer involves the April 30 FDA proposal, the difference between 'still shipping' and 'safe to bet on', and a conversation about what brand pricing looks like once she does the math on insurance.
Most coverage is either too dismissive (\"just some nausea\") or too alarmist (\"brutal stomach issues forever\"). After watching a few hundred people start tirzepatide and semaglutide over the past year, here's the actual shape of the side effects most people get.
A clinic in Bangkok used the phrase 'maintenance dose' three times in one consultation without ever defining it. The patient nodded each time. Then she asked me afterwards what it meant. The honest answer is that nobody knows for sure yet, but here's what we're learning.
Eli Lilly launched Mounjaro in NZ February 2026 via Medsafe approval; private telehealth (Well Revolution + Pocket Lab) stocking from launch week. Wegovy still pending Medsafe filing. Foundayo (orforglipron) MHRA / EMA / Medsafe trajectory all 12-18 months behind FDA. What NZ readers can do today.
Almost all the public conversation about tirzepatide is about the first six months. The trial data, the dramatic before-and-afters, the side-effects window. The second year is where the harder questions live: maintenance dose, plateau, lean mass, and the question nobody asks until they're in it.
MOH Circular 87/2024 hit its one-year anniversary in March; the in-person-consultation rule is now observable, not theoretical. Foundayo (orforglipron) HSA pathway tracking 12-18 months behind FDA. Oral Wegovy 25mg HSA filing the more imminent question. What changed for SG readers since the April buyer's guide.
What changed for UK GLP-1 access since the April 2026 buyer's guide. NHS QOF tirzepatide indicators went live April 1; Cohort 2 (BMI 35-39.9) starts June; oral Wegovy 25mg shipped at private pharmacies in January; Foundayo (orforglipron) MHRA pathway tracked. Private market still dominant. What to do today.
A reader sent me a DM at 11pm on a Sunday: appointment Monday morning, what do I actually need to ask? The list most people Google online is too long, vague, and written by someone who has never had a 15-minute appointment. Here's the shorter list that matters.
A reader at month 12 asked me what happens if she stops. The honest answer involves the trial data on weight regain, the lifestyle changes that determine how much, and a more useful frame: stopping isn't a single event, it's a process that takes about as long as starting did.
A friend got scheduled for elective surgery and her surgeon told her to pause tirzepatide for a week before. Her telehealth provider had no idea this was a thing. The list of reasons to pause is longer than most providers acknowledge, and pausing is mostly fine.
Eight US telehealth platforms scored against Panya's 11-signal rubric. Three routable (Ro, Calibrate, WW Clinic), one conditional (Found), four hold (Hims, Mochi, Henry, Eden). The April 30 FDA proposal closes the cheap-compounded-supply lane · this is the new map.
Five months after the FDA closed enforcement discretion on 503A and 503B compounded tirzepatide and semaglutide, the US compounded-GLP-1 landscape has consolidated, contracted, and fragmented. The April 30 scorecard recap captured the snapshot. This is what changed in the four weeks after.
BPOM intermittency means the existing Bali buyers guide gets stale fast. This is the May 2026 supply-state tactical · per-clinic Mounjaro and Ozempic stocking, the most-current expat-routable picks, and the Bangkok-hop fallback when the nomad-clinic layer has gaps.
Bangkok is the regional anchor for legitimately-supplied tirzepatide and semaglutide in Southeast Asia. Flight matrices, clinic-relationship cadence, cold-chain transit, customs personal-use rules per origin country, and the four-versus-twelve-week supply math.
Weekly read on what's actually in stock at the Bangkok premium hospitals and mid-tier clinics, with price changes since last digest, regulatory movements that affect supply, and the picking question for this week. New format, weekly cadence, BKK-anchored. Issue 1.
The semaglutide and tirzepatide effect on alcohol intake is real and well-documented. The mechanism is partly understood, the long-term safety data is thin, and the practical advice for users on the drug is more nuanced than 'one drink is fine.' What the 2026 SURMOUNT-OASIS and downstream trials add.
HK Department of Health licenses Wegovy + Mounjaro for limited indications. Private clinic supply is steady but premium-priced. The 1h45 Bangkok flight is the cost-arbitrage many HK-resident expats end up using. What's actually licensed, per-clinic pricing, and the picking framework.
What actually shifted in the last 60 days: Foundayo (orforglipron) approved early under the National Priority Voucher, oral Wegovy 25mg shipping, FDA proposes excluding tirzepatide from 503B bulks, RFK pulled 14 peptides off Category 2, survodutide phase 3 obesity readout. Routing impact for each.
Eli Lilly's triple agonist (GLP-1 + GIP + glucagon) has TRIUMPH-1, TRIUMPH-2, and TRIUMPH-4 readouts in the public record. Weight reduction at 12mg lands above tirzepatide. Cardiovascular signal is being watched. FDA filing window now points at late 2026. What this changes in routing decisions today.
The Singapore GLP-1 clinic layer beyond the existing buyers guide. Per-clinic pricing for the four most-routable Singapore providers, MOH-licensed-product reality, the Wegovy-vs-Ozempic supply picture, and when the 2h20 Bangkok flight beats the local cost.
The dose-step decisions most people get wrong on tirzepatide. When to stay at 5mg, when to push to 10mg, what gastrointestinal side effects actually tell you, and the muscle-loss + protein math nobody mentions until it bites.
Side-by-side comparison of the three branded GLP-1 pens available in Bangkok in May 2026. Per-month USD pricing at premium hospitals and mid-tier clinics, supply state per medication, and the picking question once cost is on the table.
The four Bangkok premium hospitals scored on Panya's 11-signal rubric: Bumrungrad, Samitivej Sukhumvit, BNH, and BDMS Wellness Clinic. JCI accreditation, real GLP-1 menu depth, BDMS-group concentration, and how Thailand-resident expats actually pick.
BIMC Hospital, Body Tonic Clinic, Cocoon Medical Spa, Siloam, Kasih Ibu. USD pricing, BPOM posture post-2025 import tightening, and how nomads + expats actually pick a Bali GLP-1 provider.
Chi Longevity, The Longevity GP, Siena Health, Noah, Ordinary Folk, Clifford Clinic. SGD pricing, MOH 87/2024 in-person-first rule, what the 11-signal rubric scores them on, and how expats actually pick.
Metabolic.Health, Endocare, Zone.Health, DarDoc, Valeo, Limitless Human, Hortman, Novomed. AED pricing, DHA / DOH posture, Foundayo arrival, and how to pick the right Emirates GLP-1 route.
Numan, Voy, Juniper, Boots, Asda, Pharmacy2U, ZAVA, Second Nature. Per-dose pricing, MHRA posture, what the rubric scores them on, and how to pick the right one for your situation.
FV Hospital, Family Medical Practice, Raffles Medical, Vinmec. USD pricing, MoH posture, supply intermittency reality, and how expats actually pick a Vietnam GLP-1 provider.
The real differences between compounded tirzepatide from a 503A pharmacy and brand Mounjaro from Eli Lilly. Regulatory status, quality control, pricing, and when one is clearly better than the other.
Longevity clinics are prescribing tirzepatide and semaglutide at fractional doses for non-obese patients. Here is what the data supports, what it does not, and the risk-benefit tradeoff.
US employer health plans often exclude weight-loss medication even when they cover Type 2 diabetes. Here is why the coverage gap exists, how to check your specific plan, and the legitimate workarounds.
The three GLP-1 drugs that matter in 2026: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide (Lilly's triple-agonist). How they differ in mechanism, weight loss, side effects, and cost.
Eight physical tells on a real Eli Lilly Mounjaro pen, what counterfeiters get wrong, and how to sanity-check a vial or pen from any source before you inject. Updated April 2026.
The SURMOUNT-4 trial tracked what happens when people stop tirzepatide after initial weight loss. Here is the honest version of the regain curve, what drives it, and how to think about maintenance.
GLP-1 drugs including tirzepatide reduce alcohol consumption for many users. Here is the mechanism, the observational data, the clinical caution, and how Panya routes patients who mention drinking on intake.
ราคา tirzepatide ในกรุงเทพปี 2026 คลินิกแบรนด์และผู้ขายตรง ช่วงราคาจริง วิธีเลือกคลินิกที่น่าเชื่อถือ และสิ่งที่ควรถามก่อนเริ่ม
Tirzepatide monthly cost across 10 markets: US brand, US compounded, UK private, Scandinavia, Germany, Thailand clinic, Thailand direct, Japan, Singapore, Australia. The real numbers, updated April 2026.
The week-by-week tirzepatide dose schedule from 2.5 mg to 15 mg, why the ramp exists, what clinics skip, and when to plateau. SURMOUNT-1-aligned, clinician-reviewed.
Roughly 25 percent of weight lost on tirzepatide is lean mass unless you intervene. The protein target, training cadence, and supplement stack that preserves muscle during GLP-1 weight loss, per Attia, Norton, and the published data.
The tirzepatide weight-loss trial that reset the market. Here is what it tested, what it found, and the parts the press skipped.
What actually happens when you start tirzepatide. What is common, what is rare, what is serious, what to do about each.
What tirzepatide is, what it costs in Bangkok, how to tell a real clinic from a mediocre one, and the questions you should ask before your first injection.
Same drug class, different receptor profile. Here is the honest comparison, without the marketing gloss.